文献速递肾移植

肾移植受者中的他汀类药物:使用情况、全因死亡率及与维持免疫抑制剂的交互作用

Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents.
PubMed 文献 · J Am Soc Nephrol · 2023-03-09

该全国性队列纳入2006至2016年间接受单肾移植且具有Medicare A/B/D部分的58264名成人,分析他汀使用与全因死亡的关系。他汀使用与死亡率降低5%相关(aHR 0.95,95%CI 0.90-0.99),且这种保护关联在mTOR抑制剂使用者中更强(aHR 0.73 vs 0.95,交互P=0.03)。

要点

  • 肾移植受者他汀使用率从移植时45.5%升至移植后5年70.9%。
  • 他汀使用与全因死亡率降低显著相关(aHR 0.95,95%CI 0.90-0.99)。
  • mTOR抑制剂使用者中他汀的保护关联更强(aHR 0.73 vs 0.95,交互P=0.03)。

核心结论

  • 真实世界证据支持他汀治疗可降低肾移植受者的全因死亡率。
  • 与基于mTOR抑制剂的免疫抑制方案联用时,他汀的有效性可能更大。

研究设计与样本

  • 全国性队列研究,纳入2006至2016年间接受单肾移植且具有Medicare A/B/D部分的58264名18岁及以上成人。
  • 他汀使用从Medicare处方药索赔数据确定,死亡从Center for Medicare and Medicaid Services记录确定。
  • 采用多变量Cox模型,将他汀使用作为时变暴露,免疫抑制方案作为效应修饰因子。

主要发现

  • 他汀使用率从移植时45.5%升至移植后1年58.2%、移植后5年70.9%。
  • 随访236944人年期间观察到9785例死亡。
  • 他汀使用与较低死亡率显著相关(aHR 0.95,95%CI 0.90-0.99)。
  • 他汀的保护关联强度因钙调神经磷酸酶抑制剂使用而异:他克莫司使用者aHR 0.97(95%CI 0.92-1.03) vs 非使用者aHR 0.72(95%CI 0.60-0.87),交互P=0.002。
  • 他汀的保护关联强度因mTOR抑制剂使用而异:使用者aHR 0.73(95%CI 0.57-0.92) vs 非使用者aHR 0.95(95%CI 0.91-1.00),交互P=0.03。

关键数值与推荐

  • 他汀使用与全因死亡率降低显著相关(aHR 0.95,95%CI 0.90-0.99)。
  • mTOR抑制剂使用者中他汀与死亡率降低的关联更强(aHR 0.73,95%CI 0.57-0.92 vs 非使用者aHR 0.95,95%CI 0.91-1.00,交互P=0.03)。

临床怎么用

  • 原文结论认为真实世界证据支持他汀治疗用于降低肾移植受者的全因死亡率。
  • 原文结论认为与基于mTOR抑制剂的免疫抑制方案联用时他汀的有效性可能更大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Cardiovascular diseases account for 32% of deaths among kidney transplant recipients. Statin therapy is common in this population. However, its effect on mortality prevention remains unclear among kidney transplant recipients, whose clinical risk profile might be unique because of concomitant immunosuppressive therapy. In this national study of 58,264 single-kidney transplant recipients, statin use was associated with a 5% decrease in mortality. More importantly, this protective association was stronger among those who used a mammalian target of rapamycin (mTOR) inhibitor for immunosuppression (27% decrease in mTOR inhibitor users versus 5% in nonusers). Our results suggest that statin therapy may reduce mortality in kidney transplant recipients and that the strength of this protective association may vary by immunosuppression regimen. BACKGROUND: Cardiovascular diseases are the leading cause of mortality in kidney transplant (KT) recipients, accounting for 32% of deaths. Statins are widely used in KT recipients, but effectiveness for preventing mortality remains unclear in this population, especially because of interaction between statins and immunosuppressive agents. We analyzed a national cohort to assess the real-world effectiveness of statins for reducing all-cause mortality in KT recipients. METHODS: We studied statin use and mortality among 58,264 adults (18 years or older) who received single kidneys between 2006 and 2016 and had Medicare part A/B/D. Statin use was ascertained from Medicare prescription drug claims and deaths from Center for Medicare and Medicaid Services records. We estimated the association of statin use with mortality using multivariable Cox models, with statin use as a time-varying exposure and immunosuppression regimen as effect modifiers. RESULTS: Statin use increased from 45.5% at KT to 58.2% at 1-year post-KT to 70.9% at 5-year post-KT. We observed 9785 deaths over 236,944 person-years. Overall, statin use was significantly associated with lower mortality (adjusted hazard ratio [aHR], 0.95; 95% confidence interval [CI], 0.90 to 0.99). The strength of this protective association varied by calcineurin inhibitor use (among tacrolimus users, aHR, 0.97; 95% CI, 0.92 to 1.03 versus among calcineurin nonusers, aHR, 0.72; 95% CI, 0.60 to 0.87; interaction P =0.002), mammalian target of rapamycin (mTOR) inhibitor use (among mTOR inhibitor users, aHR, 0.73; 95% CI, 0.57 to 0.92 versus among nonusers, aHR, 0.95; 95% CI, 0.91 to 1.00; interaction P =0.03), and mycophenolate use (among mycophenolate users, aHR, 0.96; 95% CI, 0.91 to 1.02 versus among nonusers, aHR, 0.76; 95% CI, 0.64 to 0.89; interaction P =0.002). CONCLUSION: Real-world evidence supports statin therapy for reducing all-cause mortality in KT recipients. Effectiveness might be greater when combined with mTOR inhibitor-based immunosuppression.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bae S, Ahn JB, Joseph C, et al. Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents. J Am Soc Nephrol. 2023. PMID: 36890643. doi:10.1681/ASN.0000000000000112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。